OverviewSuggest Edit

GBT (Global Blood Therapeutics) is a clinical-stage biopharmaceutical company dedicated to discovering, developing and commercializing novel therapeutics to treat grievous blood-based disorders with significant unmet need. The Company develops its lead product candidate, voxelotor, as an oral, once-daily therapy for sickle cell disease. It is also investigating GBT440 for the treatment of hypoxemic pulmonary disorders in an ongoing Phase 2a study in patients with idiopathic pulmonary fibrosis.

TypePublic
Founded2012
HQSouth San Francisco, US
Websitegbt.com
Employee Ratings4.8

Latest Updates

Employees (est.) (Dec 2019)352(+106%)
Revenue (FY, 2019)$2.1 M
Share Price (Sept 2020)$56.2 (+7%)
Cybersecurity ratingAMore

Key People/Management at GBT (Global Blood Therapeutics)

Ted W. Love

Ted W. Love

President and Chief Executive Officer
Brian Cathers

Brian Cathers

Chief Scientific Officer
Jung E. Choi

Jung E. Choi

Chief Business and Strategy Officer
Jeffrey Farrow

Jeffrey Farrow

Chief Financial Officer
Eric Fink

Eric Fink

Chief Human Resources Officer
Nazila Habibizad

Nazila Habibizad

Senior Vice President, Operations
Show more

GBT (Global Blood Therapeutics) Office Locations

GBT (Global Blood Therapeutics) has an office in South San Francisco
South San Francisco, US (HQ)
171 Oyster Point Blvd #300South
Show all (1)

GBT (Global Blood Therapeutics) Financials and Metrics

GBT (Global Blood Therapeutics) Revenue

GBT (Global Blood Therapeutics)'s revenue was reported to be $2.11 m in FY, 2019
USD

Revenue (Q2, 2020)

31.5m

Gross profit (Q2, 2020)

31.1m

Gross profit margin (Q2, 2020), %

98.8%

Net income (Q2, 2020)

(52.8m)

EBIT (Q2, 2020)

(52.0m)

Market capitalization (14-Sept-2020)

3.5b

Closing stock price (14-Sept-2020)

56.2

Cash (30-Jun-2020)

384.7m

EV

3.3b
GBT (Global Blood Therapeutics)'s current market capitalization is $3.5 b.
Annual
USDFY, 2015FY, 2016FY, 2017FY, 2018FY, 2019

Revenue

2.1m

Cost of goods sold

48.0k

Gross profit

2.1m

Gross profit Margin, %

98%
Quarterly
USDQ2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020

Revenue

14.1m31.5m

Cost of goods sold

135.0k377.0k

Gross profit

14.0m31.1m

Gross profit Margin, %

99%99%
Annual
USDFY, 2015FY, 2016FY, 2017FY, 2018FY, 2019

Cash

148.5m92.1m198.3m275.4m302.2m

Accounts Receivable

2.1m2.6m

Prepaid Expenses

3.8m6.3m4.7m

Inventories

1.3m
Quarterly
USDQ2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020

Cash

40.6m158.5m134.0m231.9m217.8m135.7m93.7m84.1m455.6m342.1m194.9m156.8m338.5m267.6m315.5m384.7m

Accounts Receivable

4.6m12.5m

Prepaid Expenses

419.0k1.6m1.9m1.6m1.7m4.0m5.0m10.4m10.3m7.1m9.0m8.2m8.2m12.7m14.1m13.5m

Inventories

14.9m27.3m
Annual
USDFY, 2015FY, 2016FY, 2017FY, 2018FY, 2019

Net Income

(46.4m)(82.5m)(117.0m)(174.2m)(266.8m)

Depreciation and Amortization

873.0k1.2m1.7m4.6m8.6m

Inventories

(1.3m)

Accounts Payable

2.7m1.1m2.8m(1.3m)4.5m
Quarterly
USDQ2, 2015

Financial Leverage

-0.7 x
Show all financial metrics

GBT (Global Blood Therapeutics) Cybersecurity Score

Cybersecurity ratingPremium dataset

A

95/100

SecurityScorecard logo

GBT (Global Blood Therapeutics) Online and Social Media Presence

Embed Graph

GBT (Global Blood Therapeutics) News and Updates

Global Blood Therapeutics stock up 40% after FDA agrees to accelerated approval pathway for sickle cell disease drug

Shares of Global Blood Therapeutics Inc. shot up 40% Monday morning after the biotech company announced it had reached an agreement with the U.S. Food and Drug Administration to use an accelerated approval pathway for a potential sickle cell disease treatment. Voxelator, a once-a-day oral drug, wor…

Lifshitz & Miller LLP Announces Investigation of Access National Corporation, Engility Holdings, Inc., Floor & Decor Holdings, Inc., Global Blood Therapeutics, Inc., Intrexon Corporation, Keryx Biopharmaceuticals, Inc., Nevada Gold & Casinos, Inc., and Sonic Corp.

NEW YORK, Nov. 1, 2018 /PRNewswire/ -- Access National Corporation (ANCX) Lifshitz & Miller announces investigation into possible breaches of fiduciary duties in connection with the sale of ANCX to Union Bankshares Corporation for 0.75 shares of Union common stock per share. If you are an ...

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Global Blood Therapeutics, Inc. - GBT

NEW YORK, Sept. 13, 2018 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Global Blood Therapeutics, Inc. ("Global Blood" or the "Company") (NASDAQ: GBT). Such investors are advised to contact Robert S. Willoughby at rswilloughby@pomlaw.com or 888-476-6529,...

SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Global Blood Therapeutics, Inc. (GBT)

NEW YORK, Sept. 13, 2018 /PRNewswire/ -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Global Blood Therapeutics, Inc. ("Global Blood" or the "Company") (NASDAQ: GBT). Such investors are encouraged to obtain...
Show more

GBT (Global Blood Therapeutics) Blogs

GBT Announces Plans to Seek Regulatory Approval for Oxbryta® (voxelotor) to Treat Sickle Cell Patients in Europe

Intends to seek full marketing authorization for Oxbryta to treat hemolytic anemia in sickle cell disease Marketing Authorization Application submission planned by mid-2021 SOUTH SAN FRANCISCO, Calif. , June 24, 2020 (GLOBE NEWSWIRE) -- Global Blood Therapeutics , Inc. (GBT) (NASDAQ: GBT) today

GBT Announces Plans to Seek Expanded Labeling for Oxbryta® (voxelotor) to Treat Children Ages 4 to 11 Years with Sickle Cell Disease

New Drug Application submission, including new age-appropriate formulation, planned by mid-2021 SOUTH SAN FRANCISCO, Calif. , June 08, 2020 (GLOBE NEWSWIRE) -- Global Blood Therapeutics , Inc. (GBT) (NASDAQ: GBT) today announced plans to expand the potential use of Oxbryta ® (voxelotor) for the

GBT Announces Participation at the Goldman Sachs 41st Annual Global Healthcare Conference Webcast

SOUTH SAN FRANCISCO, Calif. , June 02, 2020 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) today announced that it will present at the Goldman Sachs 41st Annual Global Healthcare Conference Webcast on Tuesday, June 9, 2020 , at 3:50 p.m. Eastern Time .

GBT Announces Upcoming Data Presentations During Virtual Edition of 25th Annual European Hematology Association Congress

Data include retrospective analysis of landmark STOP 2 Study highlighting correlation between higher hemoglobin levels and lower transcranial Doppler (TCD) flow velocities in children with sickle cell disease SOUTH SAN FRANCISCO, Calif. , May 14, 2020 (GLOBE NEWSWIRE) -- Global Blood Therapeutics ,

GBT Reports Recent Business Progress and First Quarter 2020 Financial Results

Achieved Oxbryta ® (voxelotor) net revenues of $14.1 million in first full quarter of launch Approximately 1,650 new patient prescriptions for Oxbryta during the first quarter Adapted to virtual operations and engagement intended to ensure ongoing access to Oxbryta during the COVID-19 pandemic

GBT to Announce First Quarter 2020 Financial Results on Wednesday, May 6, 2020

GBT to Announce First Quarter 2020 Financial Results on Wednesday, May 6, 2020 Content Import Wed, 04/29/2020 - 08:02 GBT to Announce First Quarter 2020 Financial Results on Wednesday, May 6, 2020 Apr 29, 2020 at 8:00 AM EDT This release is a backfill from a N…
Show more

GBT (Global Blood Therapeutics) Frequently Asked Questions

  • When was GBT (Global Blood Therapeutics) founded?

    GBT (Global Blood Therapeutics) was founded in 2012.

  • Who are GBT (Global Blood Therapeutics) key executives?

    GBT (Global Blood Therapeutics)'s key executives are Ted W. Love, Brian Cathers and Jung E. Choi.

  • How many employees does GBT (Global Blood Therapeutics) have?

    GBT (Global Blood Therapeutics) has 352 employees.

  • What is GBT (Global Blood Therapeutics) revenue?

    Latest GBT (Global Blood Therapeutics) annual revenue is $2.1 m.

  • What is GBT (Global Blood Therapeutics) revenue per employee?

    Latest GBT (Global Blood Therapeutics) revenue per employee is $6 k.

  • Who are GBT (Global Blood Therapeutics) competitors?

    Competitors of GBT (Global Blood Therapeutics) include Acceleron Pharma, Retrophin and Palatin Technologies.

  • Where is GBT (Global Blood Therapeutics) headquarters?

    GBT (Global Blood Therapeutics) headquarters is located at 171 Oyster Point Blvd #300South, South San Francisco.

  • Where are GBT (Global Blood Therapeutics) offices?

    GBT (Global Blood Therapeutics) has an office in South San Francisco.

  • How many offices does GBT (Global Blood Therapeutics) have?

    GBT (Global Blood Therapeutics) has 1 office.